A total of 8 out of 92 markers in the panel, including amphiregulin, MUC16, kallikrein, IL-6, syndecan-1, TGF-α, and vimentin, were found to be significantly upregulated, and this panel could be used for CRC prognosis. Here, MUC16 is linked to colorectal carcinoma.